HYLENEX® recombinant
Hypodermoclysis and subcutaneous fluid administration
ApprovedCommercial
Key Facts
Indication
Hypodermoclysis and subcutaneous fluid administration
Phase
Approved
Status
Commercial
Company
About Halozyme Therapeutics
Halozyme Therapeutics is a NASDAQ-listed biotechnology company focused on drug delivery innovation through their proprietary ENHANZE® technology platform based on the enzyme rHuPH20. The company has a dual business model, commercializing their own FDA-approved products HYLENEX® and XYOSTED® while partnering with major pharmaceutical companies to enhance their therapies with subcutaneous delivery capabilities. With over 30 years of auto-injector development expertise and multiple active partnerships, Halozyme is positioned as a leader in improving patient convenience and treatment outcomes.
View full company profile